Supravalvular Aortic Stenosis and the Risk of Premature Death Among Patients With Homozygous Familial Hypercholesterolemia

Patients with homozygous familial hypercholesterolemia (HoFH) have a high risk for premature death. Supravalvular aortic stenosis (SVAS) is a common and the feature lesion of the aortic root in HoFH. The relationship between SVAS and the risk of premature death among patients with HoFH has not been fully investigated. The current study analysis included 97 HoFH patients with mean age of 14.7 (years) from the Genetic and Imaging of Familial Hypercholesterolemia in Han Nationality Study. During the median (±SD) follow-up 4.0 (±4.0) years, 40 (41.2%) participants had SVAS and 17(17.5%) participants experienced death. The proportion of premature death in the non-SVAS and SVAS group was 7.0% and 32.5%, respectively. Compared with the non-SVAS group, SVAS group cumulative survival was lower in the HoFH (log-rank test, P<0.001). This result was further confirmed in the multivariable Cox regression models. After adjusting for age, sex, low density lipoprotein cholesterol(LDL_C)-year-score, lipid-lowering drugs, cardiovascular disease (CVD) and carotid artery plaque, SVAS was an independent risk factor of premature death in HoFH on the multivariate analysis(hazard ratio(HR) 4.45; 95% confidence interval(CI),1.10 to 18.12; P =0.037). In conclusion, a significantly increased risk of premature death was observed among HoFH patients with SVAS. Our study emphasized the importance of careful and aggressive management in these patients when appropriate.